Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies
- 1 July 2004
- journal article
- review article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 33 (1) , 83-89
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Graft-versus-leukemia reactions in allogeneic chimerasBlood, 2004
- Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignanciesBlood, 2003
- Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia--Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual DiseaseLeukemia & Lymphoma, 2003
- Targeting tumours with genetically enhanced T lymphocytesNature Reviews Cancer, 2003
- Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodiesLeukemia, 2002
- The Use of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus Induced Lymphoma in Transplant RecipientsLeukemia & Lymphoma, 2000
- Mechanisms of the Graft‐versus‐Leukemia ReactionStem Cells, 1997
- Preparation and characterization of a chimeric CD 19 monoclonal antibodyImmunology & Cell Biology, 1991
- The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysCell, 1991